Aardvark Therapeutics, Inc. (NASDAQ:AARD) CEO Purchases $264,672.00 in Stock

Aardvark Therapeutics, Inc. (NASDAQ:AARD) CEO Tien-Li Lee purchased 16,542 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average price of $16.00 per share, with a total value of $264,672.00. Following the purchase, the chief executive officer now owns 1,496,175 shares in the company, valued at $23,938,800. This represents a 1.12 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Aardvark Therapeutics Stock Performance

Shares of AARD opened at $14.90 on Thursday. Aardvark Therapeutics, Inc. has a 12 month low of $11.55 and a 12 month high of $16.48.

Aardvark Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.